NCT02393859 2024-05-29Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)AmgenPhase 3 Completed111 enrolled 23 charts 1 FDA
NCT02000427 2024-05-28Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic LeukemiaAmgenPhase 2 Completed45 enrolled 24 charts 1 FDA